Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

211 - 220 of 6604 results found

An assessment of Nigeria's health systems response to COVID-19

Date
Wednesday, February 07, 2024 - 4:00 AM
Description
CONCLUSIONS: Interventions of state and non-state actors have strengthened the health systems to some extent. However, more needs to be done to sustain these gains and make the health system resilient to absorb unprecedented shocks.

A Course Design for Remote Teaching Advanced Topics in Neuroscience

Date
Wednesday, February 07, 2024 - 4:00 AM
Description
The COVID-19 pandemic pushed educators to engage in remote teaching out of necessity, but as our relationship with teaching technology grows, remote teaching has emerged as a suitable substitute for in-person education. In this manuscript, we detail

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Date
Wednesday, February 07, 2024 - 4:00 AM
Description
CONCLUSIONS: After 16 weeks of once- or twice-daily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113 showed greater efficacy than placebo in patients with moderate-to-severe plaque psoriasis. (Funded by

Associations of COVID-19 lockdown with birth weight in China

Date
Tuesday, February 06, 2024 - 4:00 AM
Description
CONCLUSIONS: The COVID-19 lockdown measures were associated with a heavier birth weight and a higher risk of macrosomia. Early pregnancy periods may be a more susceptible exposure window for a heavier birth weight and a higher risk of macrosomia. We

A Randomized Trial of Nafamostat for Covid-19

Date
Tuesday, February 06, 2024 - 4:00 AM
Description
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label